- Molecular Templates Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Molecular Templates Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Molecular Templates Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Molecular Templates Inc To Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting TranscriptNov 11, 2022
- Molecular Templates Inc To Discuss Unique Approach To Immuno-Oncology For Solid Tumors Call TranscriptApr 13, 2022
- Molecular Templates Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Molecular Templates Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Molecular Templates Inc To Discuss The Use of Egineer Toxin Bodies (EBTs) TranscriptSep 29, 2020
- Molecular Templates Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Molecular Templates Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Molecular Templates Inc R&D Day TranscriptNov 15, 2019
- Molecular Templates Inc at UBS Global Healthcare Conference TranscriptMay 20, 2019
Molecular Templates Inc To Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting Transcript
Hello, and welcome to Molecular Templates R&D Day 2022. My name is Grace Kim, Head of Investor Relations. And before we start, I'd like to remind you that today, we'll be making some forward-looking statements, which reflect our current views and expectations around both the potential attributes of our engineered toxin body technology and around our product candidates. We caution existing and prospective investors not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For more information, please refer to our filings with the Securities and Exchange Commission. (Operator Instructions)
And at this time, it's my great pleasure to turn the program over to CEO, Eric Poma; and CMO, Roger Waltzman. Gentlemen?
Thanks, Grace. Thanks, everyone, coming both in person and online. We're going to spend the next hour or so really talking about the clinical data we're seeing. We're really excited about the early clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)